Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoquercetin is a naturally occurring flavonoid glycoside (specifically, quercetin-3-O-glucoside) found in many medicinal herbs, fruits, and vegetables[8]. It is more bioavailable than its aglycone form (quercetin), due to its glucose moiety which facilitates rapid absorption via sodium-dependent glucose transporter 1 (SGLT-1) in the small intestine[5][3]. Isoquercetin exhibits potent antioxidant activity by scavenging free radicals and inhibiting oxidative damage to cells[4][5]. It also demonstrates anti-inflammatory effects and has been studied for potential benefits in cardiovascular disease, diabetes (as an α-glucosidase inhibitor improving glucose tolerance), allergies, neurological conditions, and cancer[5][8]. Mechanistically, it inhibits protein disulfide isomerase (PDI), contributing to anticoagulant effects relevant for thromboembolism prevention in cancer patients[3]. In preclinical studies on pancreatic cancer cells, isoquercetin induces apoptosis through activation of caspases and cell cycle arrest at the G1 phase[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoquercetin.